Sevilla

• Phase 1b Study to Assess the Safety, Tolerability and Pharmacodynamics of PBFT02 in Adult Participants with Frontotemporal Dementia (FTD) an … Ended
  2023-507724-23-00 7 2024-02-01 FRONTOTEMPORAL DEMENTIA (FTD)
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• Phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in participants with unresected LA SCCHN Ended
  2023-505796-76-00 3 2024-01-18 Locally Advanced Squamous Cell Carcinoma of the Head and Neck
• RANDOMIZED, CONTROLLED, OPEN, MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION OF ANTI-TUBERCULOUS DRUGS BAS … Ended
  2023-509075-17-00 4 2024-01-17 Bacilliferous pulmonary tuberculosis
• MK-0616-013 Ended
  2022-502777-42-01 5 2024-01-16 Hypercholesterolemia
• A study evaluating the effects of GLPG3667 given as oral treatment in adults with active systemic lupus erythematosus. Ended
  2023-503183-16-00 4 2024-01-16 Systemic Lupus Erythematosus
• A randomized, multi-centre, double-blind, phase II clinical trial of dose finding of Montelukast in patients with erosive osteoarthritis of … Ended
  2023-506137-30-00 4 2024-01-11 Erosive osteoarthritis of the hands
• Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Ended
  2023-503919-15-00 3 2024-01-09 Prostatic Neoplasms
• A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade … Ended
  2023-504328-25-00 4 2023-12-27 hidradenitis suppurativa
• A Phase 2 Multicenter Study to Evaluate PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations Ended
  2023-503343-33-00 4 2023-12-21 Active Cutaneous Lupus Erythematosus (CLE) or Systemic Lupus Erythemat
• A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma. Ended
  2023-503739-16-00 1 2023-12-20 Relapsed or refractory solid tumors or non-Hodgkin lymphoma
• Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended
  2022-503160-33-00 5 2023-12-15 Hidradenitis Suppurativa
• Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended
  2023-505350-18-00 4 2023-12-15 HIV Infections
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the … Ended
  2023-503614-80-00 5 2023-12-14 Pulmonary Arterial Hypertension
• Extension Study to Assess Batoclimab in Participants with TED. Ended
  2024-512650-21-00 5 2023-12-13 Thyroid Eye Disease (TED)
• A study to learn if atrasentan is safe and works in people with IgA nephropathy who are taking an SGLT2i Ended
  2023-503828-13-00 4 2023-12-12 Nephrology
• A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim … Ended
  2023-503893-19-00 5 2023-12-06 HIV-1 infection
• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug … Ended
  2022-502001-15-00 4 2023-12-05 Acute Ischemic Stroke (AIS)
• Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to … Ended
  2022-503066-74-00 7 2023-12-04 Advanced solid tumors
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 4 2023-11-29 Knee osteoarthritis pain
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 4 2023-11-27 acute myocardial infarction
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma Ended
  2023-503418-63-00 4 2023-11-23 Head and Neck Squamous Cell Carcinoma
• A study to see how well PLS240 works in treating secondary hyperparathyroidism, and how safe it is, in end stage kidney disease participants … Ended
  2023-504338-24-00 5 2023-11-09 ESKD participants with history of secondary hyperparathyroidism (SHPT)

Showing 1,321–1,344 of 1,630 trials